TAPUR Study for Advanced Cancers

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. For more information please visit http://www.tapur.org/patients
Principal investigator
Gordon Srkalovic, MD, PhD
Trial Category
Trial SubCategory
Genomic testing based trial